Efficacy of EUS-guided Celiac Plexus Blockade in Chronic Pancreatitis

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a triple-blind, parallel group, randomized controlled trial to assess the benefit of triamcinolone injection as a therapeutic measure for control of chronic pancreatitis pain. The treatment group will undergo EUS-CPB with bupivicaine plus triamcinolone ("therapeutic block"). There control group will undergo EUS-CPB with bupivicaine alone ("diagnostic block").

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Collaborators: American Society for Gastrointestinal Endoscopy; TAP Pharmaceutical Products Inc.
• Treatments: Bupivacaine; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion criteria include:

• Age >18 yrs

• Ability for informed consent

• Chronic pancreatic-type abdominal pain (type B) (11).

Exclusion criteria include:

• Pregnancy

• Malignancy

• Recent acute pancreatitis (within 2 months)

• Elevated INR (>1.5) or low platelet count (<75 cells/mm3)

• Allergy to eggs or "caine" anesthetics or corticosteroids; AND

• Becks depression score>20.